[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"papillary-thyroid-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:papillary-thyroid-cancer":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,37,60,81,99,126,150,168,197,224,254,275,296],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":4},"100638949","clinical-utility-of-preoperative-thyroid-guidepx-testing-100638949",false,"NCT07584447","Clinical Utility of Preoperative Thyroid GuidePx® Testing","Inclusion Criteria:\n\n* Patients aged 18 years or older at the time of enrollment\n* English-speaking\n* Bethesda V or VI cytology following FNA of a thyroid nodule (papillary thyroid cancer)\n* Bethesda III or IV with ThyroSpec positive for BRAFV600E, TERT, rearrangements in BRAF, RET, NTRK1, NTRK3, RAS + TERT, RAS + EIF1AX, AKT1, PI3CA, CTNNB1, EGFR, rearrangements in ALK\n* Tumor 1- 4cm in size\n* No lymph node involvement on ultrasound\n* No gross extrathyroidal extension on ultrasound\n\nExclusion Criteria:\n\n* Prior thyroid operation\n* Distant metastatic disease\n* Personal history of thyroid cancer\n* History of whole-body radiation exposure or radiation to the head and neck region","ALL","18 Years",{"count":18,"type":19},85,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to learn whether having Thyroid GuidePx® test results available before treatment may help patients with papillary thyroid cancer and doctors make better-informed treatment decisions.",[23,24],"Papillary Thyroid Cancer","Papillary Thyroid Carcinoma","NOT_YET_RECRUITING","2026-05-28",{"date":28,"type":29},"2026-06-01","ACTUAL",{"date":31,"type":19},"2026-04",{"date":33,"type":19},"2029-04",{"name":35,"class":36},"University of Calgary","OTHER",{"id":38,"slug":39,"hasResults":11,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":4,"eligibilityCriteria":43,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":44,"enrollmentInfo":45,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":47,"conditions":48,"keywords":4,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":59},"100540442","the-clinical-outcomes-and-prediction-of-thermal-ablation-for-low-risk-papillary-thyroid-carcinoma-100540442","NCT06316895","The Clinical Outcomes and Prediction of Thermal Ablation for Low-risk Papillary Thyroid Carcinoma","The Clinical Outcomes and Artificial Intelligence Prediction Model of Ultrasound-guided Thermal Ablation for the Treatment of Low-risk Papillary Thyroid Carcinoma","Inclusion Criteria:\n\n1. patients age between 18 and 80 year old, both sex\n2. papillary thyroid carcinoma confirmed by core-needle biopsy or fine-needle aspiration\n3. the largest diameter ≤2.0 cm\n4. no clinical or imaging evidences of extrathyroidal extension, lymph node metastasis and distant metastasis on ultrasound, nech and chest CT\n5. follow-up period ≥12 months,\n\nExclusion Criteria:\n\n1. patients with convincing evidence of aggressive papillary thyroid carcinoma or other type of thyroid cancer by biopsy\n2. history of neck radiation\n3. history of thyroid surgery\n4. coagulation disorder\n5. serious heart, respiratory, liver, or renal failure\n6. dysfunction of the vocal cord on the opposite side","80 Years",{"count":46,"type":19},3772,"1. To evaluate the clinical outcomes of ultrasound-guided thermal ablation and thyroid surgery for the treatment of papillary thyroid carcinoma;\n2. To develop and validate a artificial intelligence model to predict the outcomes of ultrasound-guided thermal ablation in the treatment of papillary thyroid carcinoma;",[23],"RECRUITING","2026-03-18",{"date":52,"type":29},"2026-03-20",{"date":54,"type":29},"2024-04-01",{"date":56,"type":19},"2029-12-31",{"name":58,"class":36},"Chinese PLA General Hospital",1,{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":68,"conditions":69,"keywords":4,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":59},"100603764","radiofrequency-ablation-for-management-of-benignindeterminate-thyroid-nodules-and-low-risk-papillary-thyroid-cancers-100603764","NCT07140757","Radiofrequency Ablation for Management of Benign\u002FIndeterminate Thyroid Nodules and Low Risk Papillary Thyroid Cancers","Eligibility Criteria\n\n1. Participants scheduled to undergo ultrasound-guided RFA for the following conditions: benign thyroid nodules, indeterminate thyroid nodules, low-risk DTC, and recurrent PTC\n2. Participant is over 18 years and is either not a surgical candidate or has declined surgery.\n3. Capable and willing to provide written informed consent\n4. Participant has one of the following diagnoses:\n\n   * Biopsy-proven benign thyroid nodules causing compressive and\u002For cosmetic symptoms who are requesting treatment,\n   * Biopsy-proven indeterminate nodules (AUS or follicular neoplasm)\n   * Papillary thyroid carcinoma (PTC) without metastasis\n   * Locally recurrent thyroid cancer (\\\u003C 2 cm).\n\nExclusion Criteria\n\n1. Participants meeting any of the following criteria will be excluded:\n2. Participants considered unsuitable for RFA by the treating physician",{"count":67,"type":19},50,"To track the outcomes of patients who have been treated with RFA and its long-term effectiveness, and to learn more about the quality of life of patients who have received RFA in this study.",[70,23,71],"Low Risk","Radiofrequency Ablation","2026-03-10",{"date":74,"type":29},"2026-03-11",{"date":76,"type":29},"2025-08-18",{"date":78,"type":19},"2030-12-31",{"name":80,"class":36},"M.D. Anderson Cancer Center",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":59},"100526333","concordance-of-molecular-classification-based-on-fine-needle-biopsy-fnb-and-surgical-samples-100526333","NCT06133374","Concordance of Molecular Classification Based on Fine Needle Biopsy (FNB) and Surgical Samples","Inclusion Criteria:\n\n* Age ≥ 18 years\n* A diagnosis of papillary thyroid cancer based on a fine needle biopsy (FNB) interpreted as a Bethesda V or VI cytology\n* A diagnosis of Atypia of Undetermined Significance (AUS) or Follicular Lesion of Undetermined Significance (FLUS) interpreted as Bethesda III or IV cytology (indeterminate nodule) ThyroSpec positive for BRAFV600E, TERT, rearrangements in BRAF, RET, NTRK1, NTRK3, RAS + TERT, RAS + EIF1AX, AKT1, PI3CA, CTNNB1, EGFR, rearrangements in ALK\n* Tumor size \\> 1 cm in maximal diameter on imaging prior to surgery\n* The patient is an operative candidate\n* The patient has provided consent\n\nExclusion Criteria:\n\n* History of radiation to the neck for situations such as medical radiation, radiation exposure in a work environment (nuclear power plant\u002Freactor), or radiation exposure through release of radioactive materials into the nearby environment from a nuclear power plant\u002Freactor.\n* Unable or unwilling to have a fine needle biopsy\n* Unwilling to undergo thyroidectomy\n* Final pathology does not demonstrate papillary thyroid cancer\n* Cases where there is no clear dominant nodule\n* Cases where there are multiple nodules that preclude sampling of a defined nodule",{"count":88,"type":19},130,"The purpose of this study is to determine whether results from a fine needle biopsy are the same as results from a larger sample that is acquired from the surgical pathology using the Thyroid GuidePx® test in patients with papillary thyroid carcinoma.",[23],"2026-01-13",{"date":93,"type":29},"2026-01-15",{"date":95,"type":29},"2024-07-01",{"date":97,"type":19},"2028-05-30",{"name":35,"class":36},{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":109,"phases":110,"briefSummary":112,"conditions":113,"keywords":114,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":59},"100620213","phase-4-application-of-mitoxantrone-hydrochloride-injection-in-transoral-robotic-thyroid-cancer-surgery-100620213","NCT07354698","Application of Mitoxantrone Hydrochloride Injection in Transoral Robotic Thyroid Cancer Surgery","MHI","Inclusion Criteria:\n\n* Age 18-65 years old, both male and female;\n* Preoperative neck ultrasound and\u002For puncture pathology suggested thyroid cancer, and postoperative pathology diagnosed thyroid cancer (tumor diameter \\\u003C4cm);\n* There are no obvious contraindications to surgery during routine preoperative examination;\n* Meet the indications for thyroid lobe\u002Ftotal resection + unilateral\u002Fbilateral central lymph node dissection;\n* Subjects voluntarily join this study, sign the informed consent form, have good compliance, and cooperate with follow-up. 4.2 Exclusion Criteria\n\nExclusion Criteria:\n\n* Those who have a history of severe drug allergy or are allergic to the drugs in this study;\n* Those with serious primary diseases such as cardiovascular and cerebrovascular, liver, kidney, and hematological system;\n* Combined with parathyroid disease or other calcium and phosphorus metabolism-related diseases;\n* Benign thyroid lesions;\n* Received mitoxantrone treatment within 4 weeks;\n* Enrolled in other clinical studies at the same time;\n* Known history of psychotropic drug abuse, alcohol abuse or drug abuse;\n* Pregnant or lactating women;\n* According to the investigator's judgment, the subject has other factors that may cause him to be forced to terminate the study midway, such as suffering from other serious diseases (including mental illness) requiring combined treatment, serious abnormal laboratory examination values, family or social factors, which may affect the safety of the subject or the collection of trial data.","65 Years",{"count":108,"type":19},114,"INTERVENTIONAL",[111],"PHASE4","Dear Patient, You are invited to participate in a clinical study investigating the Application of Mitoxantrone Hydrochloride Injection for Lymphatic Tracing in Transoral Robotic Thyroid Cancer Surgery. This protocol (Protocol No.: \\[To be filled\\]) has been reviewed and approved by the Ethics Committee of the Army Center of Specialized Medicine.\n\nI. Background and Objectives 1.1 Disease Burden and Current Treatments 1.1.1 Thyroid Cancer Surgery Thyroid cancer, the most common head and neck malignancy, exhibits rising global incidence. Central compartment lymph nodes are frequent sites of metastasis in papillary thyroid carcinoma (PTC). Transoral endoscopic thyroid surgery offers superior cosmesis versus open surgery. The da Vinci® robotic system enhances visualization and instrument maneuverability, overcoming technical limitations of narrow endoscopic operating channels.\n\n1.1.2 Lymphatic Tracers in Thyroid Surgery\n\nMitoxantrone Hydrochloride Injection for Lymphatic Tracing is China's only approved tracer for thyroid lymphatic mapping. Its high lymphotropic specificity enables:\n\nLymph node mapping: Forms nanocrystals that permeate lymphatics, staining nodes blue.\n\nParathyroid negative imaging: Spares parathyroid glands, aiding their identification and reducing postoperative hypocalcemia.\n\n1.2 Study Objectives\n\nPrimary: Compare lymph node dissection efficacy and parathyroid protection between:\n\nIntervention: Transoral robotic thyroid lobectomy\u002Ftotal thyroidectomy + central neck dissection (CND) with lymphatic tracing.\n\nControl: Identical surgery without tracing.\n\nSecondary:\n\n1. Compare postoperative parathyroid function between groups.\n2. Evaluate tracer sensitivity for metastatic lymph nodes.\n\n1.3 Participating Site and Sample Size Site: Army Center of Specialized Medicine Sample: 114 treatment-naïve PTC patients scheduled for transoral robotic surgery (Jan-Dec 2024).\n\nIntervention group (n=57): Mitoxantrone Hydrochloride tracing Control group (n=57): No tracer II. Study Procedures Pre-study: Medical history review, preoperative assessments, and documentation of concomitant medications (30 days postsurgery).\n\nIntervention:\n\nThyroid exposure → Intervention group: Multisite intraglandular tracer injection (0.1 mL\u002Fsite, depth ≈0.3 cm; total dose thyroid-dependent).\n\nBoth groups: Thyroid lobectomy\u002Ftotal thyroidectomy ± unilateral\u002Fbilateral CND. Intraoperative recording: Thyroid characteristics, tracer dose\u002Finjection sites, lymphadenectomy duration.\n\nPathology:\n\nTotal lymph node yield and blue-staining rate. Intraoperative frozen section + final histopathology for metastatic nodes.\n\nFollow-up (Postoperative Day 7±3):\n\nPhysical exam, vital signs, lab tests (CBC, biochemistry, thyroid\u002Fparathyroid hormones, electrolytes).\n\n12-lead ECG. Safety monitoring: Adverse events (AEs) tracked until Postoperative Day 14. III. Potential Benefits Improved lymphatic mapping → Reduced parathyroid injury, enhanced lymph node clearance, lower AE rates.\n\nTracer provided at no cost by the sponsor. Note: Efficacy is not guaranteed. Alternative treatments exist. IV. Risks and Inconveniences Potential AEs: Per product labeling and surgical risks. Procedural burdens: Multiple hospital visits and tests. AE management: Immediate medical intervention provided. Compensation per GCP regulations if injury is trial-related.\n\nV. Costs Tracer: NMPA-approved and insurance-covered. Routine care\u002Fmedications: Patient\u002Finsurance responsibility. AE compensation: Sponsor-covered if causally related (per Chinese GCP). VI. Confidentiality\n\nMedical records accessible only to:\n\nResearch team Ethics Committee Regulatory authorities No personally identifiable data will be published. VII. Contact Information Ethics Committee: 68757140 Principal Investigator: Dr. Yan Xu \u002F TEL: 68729250 VIII. Voluntary Participation Right to withdraw anytime without penalty. Investigator may discontinue your participation for safety\u002Fadministrative reasons.\n\nExit assessments may be required. IX. Decision Process Discuss with your physician\u002Ffamily. Retain this document.\n\nParticipant Signature: \\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_ Date: \\_\\_\\_\\_\\_\\_\\_\\_\\_\n\nInvestigator Signature: \\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_ Date: \\_\\_\\_\\_\\_\\_\\_\\_\\_",[23],[115,116],"Mitoxantrone Hydrochloride Injection","Transoral Robotic Surgery","2026-01-12",{"date":119,"type":29},"2026-01-21",{"date":121,"type":19},"2026-02-01",{"date":123,"type":19},"2028-02-01",{"name":125,"class":36},"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":15,"minAge":133,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":149},"100441176","targeted-therapy-to-increase-rai-uptake-in-metastatic-dtc-100441176","NCT05024929","Targeted Therapy to Increase RAI Uptake in Metastatic DTC","Targeted Therapy to Increase RAI Uptake in Patients With Metastatic Differentiated Thyroid Cancer","Inclusion Criteria (Prospective Cohort):\n\n1. Patients with a histologic diagnosis of differentiated thyroid cancer\n2. Presence of an neurotrophic tyrosine kinase receptors (NTRK)-fusion, RET-fusion, anaplastic lymphoma kinase (ALK)-fusion, BRAF V600 mutation, BRAF-fusion or other targetable alteration identified in a Clinical Laboratory Improvement Amendments\u002FCollege of American Pathologists (CLIA\u002FCAP) laboratory\n3. Anatomically evaluable disease on chest Computed tomography (CT) meeting oneo f the following criteria (obtained within 180 days of enrollment):\n\n   1. multiple (10 or more) noncalcified solid pulmonary nodules visible on CT and\u002For\n   2. enlarging, discrete pulmonary nodules visible on CT of any number consistent with metastatic disease\n4. Patients for whom systemic therapy with an oncogene-specific kinase inhibitor is planned from commercial supply or as part of a separate therapeutic clinical trial (that does not include data sharing with this protocol)\u002Fcompassionate access protocol\u002Fsingle patient investigational new drug (IND). Such agents include, but are not limited to:\n\n   1. Larotrectinib, entrectinib, selitrectinib, and repotrectinib for NTRK fusions\n   2. Selpercatinib and pralsetinib for RET fusions\n   3. Crizotinib, lorlatinib, repotrectinib, and alectinib for ALK fusions\n   4. Dabrafenib and\u002For trametinib for BRAF V600 mutations\n   5. Oncogene-specific kinase inhibitors other than those specifically delineated above must be approved by the overall study PI prior to enrollment\n\nInclusion Criteria (Data Sharing Cohort):\n\n1\\. Patients enrolled on other oncogene-specific targeted therapy trials who undergo whole body thyroid scan approximately 28 days after beginning targeted therapy and agree to data sharing as part of the consent process for that trial.\n\nExclusion Criteria (All Cohorts):\n\n1. No prior oncogene-specific targeted therapy allowed. However, patients may enroll within 4 weeks of starting oncogene-specific therapy if a pre-therapy WBS is available. Prior therapy with non-oncogene specific multi-thyrosine kinase inhibitors (such as sorafenib, lenvatinib, and\u002For cabozantanib) is allowed.\n2. Females who are pregnant or breastfeeding are excluded due to the potential risks of the RAI used in the WBS to the fetus\u002Fneonate.\n3. Patients who require sedation\u002Fgeneral anesthesia to complete a WBS are excluded.\n4. U.S. Military Personnel are excluded due to the Children's Hospital of Philadelphia (CHOP) Institutional Review Board (IRB) requirements.","0 Years",{"count":135,"type":19},32,"Papillary thyroid cancer (PTC) is a common type of differentiated thyroid cancer (DTC) in children and represents the second most common cancer in adolescent females. Recently targeted drugs that block many of the genetic drivers of DTC have become available. While Investigators know that these drugs shrink DTC tumors in many cases, the impact on radioactive iodine (RAI) avidity has not been systematically studied.",[23,138,139],"Pediatric Cancer","Differentiated Thyroid Cancer","2025-11-12",{"date":142,"type":29},"2025-11-14",{"date":144,"type":29},"2021-07-16",{"date":146,"type":19},"2033-02-01",{"name":148,"class":36},"Children's Hospital of Philadelphia",9,{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":159,"conditions":160,"keywords":4,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":167,"locationsCount":59},"100572474","ultrasound-guided-thermal-ablation-for-papillary-thyroid-carcinoma-100572474","NCT06733740","Ultrasound-guided Thermal Ablation for Papillary Thyroid Carcinoma","The Clinical Outcomes of Ultrasound-guided Thermal Ablation for the Treatment of Papillary Thyroid Carcinoma: A Multicenter Study","Inclusion Criteria:\n\n1. patients age between 18 and 80 year old, both sex\n2. papillary thyroid carcinoma confirmed by core-needle biopsy or fine-needle aspiration\n3. the largest diameter ≤2.0 cm\n4. no clinical or imaging evidences of extrathyroidal extension, lymph node metastasis and distant metastasis on ultrasound, neck and chest CT\n5. follow-up period ≥12 months\n\nExclusion Criteria:\n\n1. patients with convincing evidence of aggressive papillary thyroid carcinoma or other type of thyroid cancer by biopsy\n2. history of neck radiation\n3. coagulation disorder, serious heart, respiratory, liver, or renal failure\n4. dysfunction of the vocal cord on the opposite side",{"count":158,"type":19},3000,"To evaluate long-term outcomes of ultrasound-guided thermal ablation for the treatment of papillary thyroid carcinoma",[23],"2025-02-13",{"date":163,"type":29},"2025-02-14",{"date":165,"type":29},"2024-12-10",{"date":78,"type":19},{"name":58,"class":36},{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":175,"sex":15,"minAge":16,"maxAge":176,"enrollmentInfo":177,"targetDuration":4,"studyType":109,"phases":179,"briefSummary":181,"conditions":182,"keywords":184,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":59},"100577606","a-study-of-online-follow-up-in-patients-with-papillary-thyroid-cancer-100577606","NCT06800482","A Study of Online Follow-up in Patients With Papillary Thyroid Cancer","A Randomized Controlled Study of Online Outpatient Follow-up in Patients With Papillary Thyroid Cancer After Surgery","Inclusion Criteria：\n\n* clinical diagnosis of papillary thyroid cancer\n* has underwent thyroid surgery (including endoscopic and open thyroid surgery)\n* 18 to 90 years of age\n* spoke Chinese\n* has the ability to use mobile phones and the Internet to complete the visit\n* voluntarily participate in clinical trials and sign informed consent.\n\nExclusion Criteria：\n\n* postoperative hospital stay more than 5 days\n* inability to complete an online visit (no access to the device or the Internet\n* high risk of postoperative complications (recurrent laryngeal nerve injury, etc.)\n* unable to participate due to comorbidities, laboratory test results or physical disability\n* pregnancy\n* has mental illness or take psychotropic drugs, and were not able to perform the surgery",true,"90 Years",{"count":178,"type":19},388,[180],"NA","The randomized, actively controlled, non-inferiority trial is scheduled to begin in August 2024 and run through August 2026. Inclusion criteria: (1) has undergone microwave ablation of thyroid or thyroidectomy (including endoscopy and opening) at the Department of Thyroid Surgery of West China Hospital of Sichuan University, (2) is between 18 and 90 years old, (3) speaks Chinese, (4) has the email address and operational ability required to complete the visit, (5) does not have a mental illness or take psychotropic drugs, (6) Voluntarily participate in clinical trials and sign informed consent. Exclusion criteria: (1) postoperative hospital stay more than 3 days; (2) Inability to complete an online visit (no access to the device or the Internet); (3) High risk of postoperative complications (recurrent laryngeal nerve injury, etc.); (4) Inability to participate due to a medical condition, laboratory test results, or physical disability (as determined by the principal investigator or surgeon).\n\nThe online outpatient follow-up was completed by thyroid surgeons of West China Hospital. Informed consent signed with a voluntary participant after a research team member contacts the patient and introduces the patient to the study. The investigators who contacted, enrolled, and randomly assigned patients included the principal investigator, the study coordinator, and the research assistant who had been specially trained in the study.\n\nAccording to the agreement, the participants randomly assigned to online visits will cross over with offline visits and withdraw from the clinical trial if :(1) unresolved technical issues, (2) inability to perform a full evaluation, (3) need\u002Frequest prescription painkillers, and (4) additional care recommended by a physician. Other cross-cutting reasons include patient requests and scheduling conflicts.\n\nThe information department of WestChina hospital obtained online and offline participants' demographic data and comorbidities, related information of chief complaint (including time of illness, information of last visit, drugs being used, contents of consultation, disease symptoms, conclusions of consultation, etc.), and online and offline outpatient information (including application time, reception time, patient satisfaction, etc.). Whether to prescribe medicine, whether to prescribe examination\u002Fadmission certificate, outpatient cost, number of questions, number of return visits, etc.) Employment, living conditions and the highest education level were obtained through the questionnaire survey at the time of enrollment, and the information about participant experience and satisfaction was obtained through the questionnaire survey after follow-up. The investigators recorded the diagnosis and treatment details of the patients at three online\u002Foffline follow-up visits at 1, 3, and 6 months after surgery. The investigators reviewed the electronic medical record 30 days after the last follow-up to monitor for adverse events. Participants were surveyed by email 30 days after the last follow-up to assess adverse events, including readmissions. If the survey is not answered within a week, an electronic reminder is sent and two attempts are made to contact the participants by phone.",[183,23],"Thyroid",[185,186,187],"Papillary thyroid cancer","surgery","out-patient","2025-01-28",{"date":190,"type":29},"2025-01-30",{"date":192,"type":29},"2024-08-07",{"date":194,"type":19},"2026-10-07",{"name":196,"class":36},"West China Hospital",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":15,"minAge":204,"maxAge":44,"enrollmentInfo":205,"targetDuration":4,"studyType":109,"phases":207,"briefSummary":209,"conditions":210,"keywords":211,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":59},"100576877","phase-3-a-clinical-study-on-the-benefits-of-carbon-nanoparticles-injection-time-in-patients-with-thyroid-cancer-100576877","NCT06791005","A Clinical Study on the Benefits of Carbon Nanoparticles Injection Time in Patients With Thyroid Cancer.","A Comparative Study of Preoperative and Intraoperative Carbon Nanoparticles Injection in Patients Undergoing Thyroid Cancer Surgery","Inclusion Criteria:\n\n* Preoperative pathological assessment indicated the presence of thyroid cancer with a maximum diameter of less than 4 cm.\n* Postoperative pathological evaluation confirmed bilateral thyroid cancer or lateral lymph node metastasis.\n* Vocal cord examination conducted one week prior to surgery revealed no abnormalities.\n* The patient had no history of prior thyroid surgery and required a total thyroidectomy.\n* Blood pressure was stably controlled.\n* The patient regained consciousness and was able to communicate normally.\n\nExclusion Criteria:\n\n* Prior to enrollment, the patient had received radiotherapy, chemotherapy, or isotope therapy.\n* A documented history of thyroid surgery.\n* Age under 16 years.\n* Known allergies to the medications under investigation or an inability to tolerate surgical intervention.\n* Presence of a retrosternal thyroid tumor.\n* Tumor invasion of the parathyroid glands and\u002For the recurrent laryngeal nerve during surgical procedures.\n* Postoperative pathology suggestive of medullary carcinoma or undifferentiated carcinoma.\n* Development of a postoperative tracheal fistula.","16 Years",{"count":206,"type":19},400,[208],"PHASE3","The detection rate of thyroid cancer (PTC) has increased rapidly in recent years. Except undifferentiated cancer, surgery is still one of the most important treatments for all types of thyroid cancer, and there is a consensus to use the lobes of the gland as the minimum extent of resection. In the meantime, a basic consensus has been reached that central zone lymph node (VI) dissection is the minimum extent of lymph node dissection. In clinical practice, neck surgery and lumpectomy are mostly performed. Hypoparathyroidism and recurrent laryngeal nerve injury are the most common complications of radical surgery for thyroid cancer, both in open surgery and the luminal approach. Once these complications occur, they have a serious impact on the quality of life of patients in the postoperative period. A number of contrast agents are now being used to help minimize complications. Carbon nanoparticles are an effective and non-harmful negative developer, and many studies have confirmed that carbon nanoparticles can be used to identify parathyroid glands in thyroid surgery. Intraoperative injection of nanocarbon is effective in increasing the quality of intraoperative parathyroid detection and lymph node clearance and reducing adverse effects, such as postoperative hypokalemia.However, there is no complete clinical guideline for preoperative intraglandular injection of carbon nanoparticles, and there is no standardized dosage for appropriate injection time, injection dose, and injection method. At the same time, there is still the problem of carbon nanoparticle leakage. At our medical center, we have found that preoperative injection of carbon nanoparticles via ultrasound-guided fine needle puncture may yield better results by reducing CNS exudation in the surgical area. In this study, we will collect more than 400 patients who underwent thyroidectomy in 2025 and underwent carbon nanoparticle injections at different time points and analyzed their intraoperative and postoperative conditions as a basis for analyzing the difference in patient benefits between preoperative and intraoperative carbon nanoparticle injections and to provide data to support the clinical use of carbon nanoparticles.",[23],[23,212,213,214],"thyroid surgery","developer","complication","2025-01-18",{"date":217,"type":29},"2025-01-24",{"date":219,"type":29},"2025-01-01",{"date":221,"type":19},"2025-09-30",{"name":223,"class":36},"Second Affiliated Hospital of Xi'an Jiaotong University",{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":15,"minAge":231,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":109,"phases":234,"briefSummary":236,"conditions":237,"keywords":243,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":253},"100490656","phase-2-restor-i-131-upt--selpercatinib-in-ret-f-p-rai-r-tc-100490656","NCT05668962","Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC","Restoration of Radioiodine Uptake with Selpercatinib in RET Fusion-Positive Radioiodine-Refractory Thyroid Cancer: a Phase 2 Study Performed in Collaboration with the International Thyroid Oncology Group (ITOG)","Inclusion Criteria:\n\n* Participants must have histologically- or cytologically-confirmed follicular-derived nonanaplastic thyroid cancer that is metastatic and\u002For unresectable AND harbors a known oncogenic RET gene fusion, performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified or equivalently accredited diagnostic laboratory.\n* Tumor tissue or liquid biopsy-based next-generation sequencing (NGS), quantitative polymerase chain reaction (qPCR), and fluorescence in situ hybridization (FISH) for RET gene fusion detection will be permitted.\n* Participants ≥ 18 years of age must have measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.\n\n  \\-- Participants 12 to \\\u003C18 years of age may enroll with either evaluable (i.e. anatomically visible tumor on cross sectional imaging, but tumors do not need to be \\>1 cm) or measurable disease per RECIST v1.1.\n* Participants should have no single tumor deposit exceeding 4.0 cm in the greatest dimension.\n* Participants must have RAI-refractory disease, as defined by:\n\n  * The malignant tissue does not concentrate RAI on a whole body scan following radioiodine administration\n  * The tumor tissue has lost the ability to concentrate RAI on a whole body scan following radioiodine administration after previous evidence of uptake at any earlier timepoint,\n  * RAI is taken up in some but not all tumor deposits on a whole body scan following radioiodine administration and\u002For\n  * There is progressive disease per RECIST v1.1 despite RAI uptake on a whole body scan following radioiodine administration and\u002For\n  * For patients 12 to \\\u003C18 years of age, there is persistent anatomically visible tumor on cross sectional imaging following prior therapeutic radioiodine administration\n* Participants may have received no more than a total cumulative RAI dose for treatment (not including RAI given for diagnostic purposes only) of 500 mCi (18.5 GBq).\n* Participants must have asymptomatic or minimally symptomatic disease, as judged by the treating investigator. For example, patients with bone metastasis associated with mild pain not requiring narcotics for pain control, or patients with lung metastasis associated with mild cough that does not limit the participant's activities, may be considered minimally symptomatic. If confirmation of this criterion is needed, discussion with the protocol chairperson is required prior to enrollment.\n* Prior external beam radiotherapy is allowed. For participants with disease limited to a prior radiotherapy field, this must be considered measurable per RECIST v1.1.\n* Participants may have had no more than one prior systemic therapy for RAI-refractory thyroid cancer, including lenvatinib, sorafenib, or other MKIs. This also includes chemotherapy and\u002For targeted therapy administered within a clinical trial, but does not include I-131 NaI or levothyroxine. Prior RET-specific kinase inhibitor therapy, such as selpercatinib and pralsetinib, is not allowed.\n* At least 28 days must have passed since any prior radiation or major surgery. At least 28 days must have passed since any prior systemic therapy for thyroid cancer, excluding thyroid hormone replacement.\n* Participants must be ≥18 years of age. Patients as young as 12 years of age will be allowed if permitted by local regulatory authorities and institutional review boards.\n\n  \\-- All patients of 12 to \\\u003C 18 years of age will be asked to provide assent and the legally designated representative will be asked to provide written consent.\n* Participants ≥ 16 years of age must have an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1. Participants 12 to \\\u003C16 years of age must have a Lansky Performance Score of ≥ 60.\n* Participants must have a life expectancy greater than 12 months.\n* Participants must have the ability to swallow medications and have no gastrointestinal abnormality that may alter medication absorption.\n* Participants must have adequate organ and marrow function as defined below. Bloodwork must be collected within 7 days prior to Cycle 1 Day 1:\n\n  * leukocytes ≥3,000\u002FmcL\n  * absolute neutrophil count (ANC) ≥1,500\u002FmcL\n  * platelets ≥100,000\u002FmcL\n  * hemoglobin ≥9 g\u002FdL\n  * total bilirubin ≤ 1.5 × institutional upper limit of normal (ULN) OR \\\u003C3.0 x institutional ULN for participants with Gilbert syndrome\n  * AST(SGOT)\u002FALT(SGPT) ≤2.5 × institutional ULN OR ≤5 × institutional ULN if the liver has tumor involvement\n  * creatinine ≤ institutional ULN OR creatinine clearance ≥30 mL\u002Fmin\n* Participants must have serum potassium, calcium and magnesium levels within institutional range of normal (may be receiving supplements). Bloodwork must be collected within 7 days prior to Cycle 1 Day 1.\n* Known human immunodeficiency virus (HIV)-infected participants on effective anti- retroviral therapy with an undetectable viral load within 6 months are eligible for this trial.\n* For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n* Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\n* Participants with treated brain metastases are eligible if the patient is asymptomatic AND follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression.\n* Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. For example, participants with nonmelanoma skin cancer, carcinoma in situ of the cervix or malignancy diagnosed ≥2 years previously and not currently receiving anticancer treatment are eligible. Patients receiving adjuvant hormone therapy for breast or prostate cancer with no evidence of disease are eligible.\n* Participants with known history or current symptoms of cardiac disease or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants should be class 2B or better.\n* Selpercatinib may impair fertility in men and women. The effects of selpercatinib on the developing human fetus are unknown. For this reason and because selpercatinib as well as other therapeutic agents used in this trial may be teratogenic, women of child-bearing potential (WOCBP) and men must agree to use highly effective contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and for 6 months after the last dose of study drug. Unless not allowed by local regulations, WOCBP who are abstinent (if this is complete abstinence, as their preferred and usual lifestyle) or in a same-sex relationship (as part of their preferred and usual lifestyle) must agree to either remain abstinent or stay in a same-sex relationship without sexual relations with males. Periodic abstinence (e.g. calendar, ovulation, symptothermal, postovulation methods), declaration of abstinence just for the duration of the trial, and withdrawal are not acceptable methods of contraception. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men with partners who are WOCBP must agree to use a highly effective contraceptive method during treatment with the study drugs and for 6 months following the last dose of study drug.\n* WOCBP must have a negative pregnancy test (serum or urine) within 7 days prior to initiating study treatment, and not be breast-feeding within two months prior to study entry, during treatment, and for ≥1 week after the last dose of study therapy.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Participants who have had chemotherapy, MKI or radiotherapy within 4 weeks.\n* Participants who have had I-131 NaI treatment within 12 months.\n* Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \\> Grade 1) with the exception of alopecia.\n* Participants who are receiving any other investigational agents.\n* Participants with symptomatic CNS metastasis or lesions threatening for spinal cord compression are not eligible.\n* Participants with clinically significant active cardiovascular disease or history of Torsades de pointes, history of myocardial infarction within 6 months prior to planned start of study treatment, or prolongation of the corrected QT interval by Fridericia's formula (QTcF) \\>470 msec on more than one ECG during Screening. Correction of suspected drug-induced QTcF prolongation may be attempted at the investigator's discretion if clinically safe to do so.\n* Participants with uncontrolled hypertension at screening, as defined by \\>160\u002F95 mm Hg.\n* Participants with uncontrolled hypertension at screening may be re-screened after appropriate medical therapy for hypertension.\n* Participants with an active uncontrolled systemic bacterial, viral, or fungal infection or serious ongoing intercurrent illness, such as hypertension or diabetes, despite optimal treatment, a clinical diagnosis or symptoms of interstitial lung disease, or other serious medical conditions which in the medical judgment of the investigator would prevent the patient from safely participating (screening for chronic conditions is not required).\n* Participants with uncontrolled symptomatic hyperthyroidism or hypothyroidism.\n* Participants with symptomatic hypercalcemia or hypocalcemia.\n* Participants with active hemorrhage or at significant risk for hemorrhage.\n* Participants who are taking a concomitant medication that is known to cause QTc prolongation ).\n* Participants with clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal absorption of the drug.\n* Participants with other uncontrolled serous intercurrent illness that would interfere with the ability to proceed with study therapy.","12 Years",{"count":233,"type":19},30,[235],"PHASE2","This research is being done to determine the efficacy of selpercatinib to restore radioactive iodine (I-131 NaI) uptake and allow for I-131 treatment in people with RET fusion-positive radioiodine-refractory thyroid cancer.\n\nThis research study involves the study drug selpercatinib in combination with standard of care treatments, I-131 and thyrotropin alfa (rhTSH).",[238,239,240,241,242,23],"Thyroid Cancer","Thyroid Carcinoma","Metastatic Thyroid Cancer","Follicular Thyroid Cancer","Unresectable Thyroid Gland Carcinoma",[238,239,240,241,242,185],"2024-12-07",{"date":246,"type":29},"2024-12-12",{"date":248,"type":29},"2023-03-01",{"date":250,"type":19},"2026-01-01",{"name":252,"class":36},"Massachusetts General Hospital",6,{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":260,"eligibilityCriteria":261,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":262,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":59},"100498118","definition-of-mutational-profile-of-papillary-thyroid-tumors-by-mass-array-100498118","NCT05766098","Definition of Mutational Profile of Papillary Thyroid Tumors by Mass-ARRAY","Caratterizzazione Del Profilo Mutazionale Nel Tumore Papillare Della Tiroide Tramite Tecnologia Mass-ARRAY","PTC-ARRAY","Inclusion Criteria:\n\n* patients with papillary thyroid cancer\n* patients whose tumor tissue can be recovered for genetic analysis\n\nExclusion Criteria:\n\n* patients who did not give consent\n* patients lost to follow-up\n* tumor samples not suitable for genetic analysis",{"count":263,"type":19},600,"Somatic mutations in the MAP (mitogen-activated protein) kinase pathway have been found in about 80% of papillary thyroid tumors (PTCs). The evaluation of the PTC mutational profile is crucial for the definition of the prognosis and for predicting the effects of targeted and personalized therapies. Molecular characterization by mass spectrometry (Mass ARRAY) allows the search for multiple mutations in a single experiment, in a sensitive, fast and economic way. A Mass ARRAY platform (PTC-MA) was developed, capable of identifying the presence of the most common somatic point mutations and rearrangements in PTC (Pesenti et al., Endocrine 2017). The aim of the study is to characterize the mutational profile of a large series of papillary thyroid carcinomas (PTC). Tumor samples will be analyzed using our PTC-MA platform. The molecular profile of PTCs will be correlated with the clinical and prognostic characteristics of the patients.",[23],"2024-10-03",{"date":268,"type":29},"2024-10-08",{"date":270,"type":29},"2019-01-08",{"date":272,"type":19},"2027-12-31",{"name":274,"class":36},"Istituto Auxologico Italiano",{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":281,"enrollmentInfo":282,"targetDuration":4,"studyType":109,"phases":284,"briefSummary":285,"conditions":286,"keywords":4,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":295,"locationsCount":59},"100552100","improvements-in-thyroid-tumor-surgery-and-the-prognosis-diagnosis-recurrence-and-metastasis-of-patients-100552100","NCT06468696","Improvements in Thyroid Tumor Surgery and the Prognosis, Diagnosis, Recurrence and Metastasis of Patients","Inclusion Criteria:\n\n1. Perform transthoracic endoscopic thyroidectomy via breast approach;\n2. Postoperative pathology confirms benign or malignant thyroid tumors;\n3. Preoperative thyroid ultrasound or cervical CT suggests no extrathyroidal invasion or distant metastasis of the tumor;\n4. No contraindications for general anesthesia;\n5. Patients with cosmetic requirements.\n\nExclusion Criteria:\n\n1. Underwent transthoracic endoscopic thyroidectomy;\n2. Postoperative pathology confirmed as benign or malignant thyroid tumors;\n3. Preoperative thyroid ultrasound or neck CT suggested no extraglandular invasion or distant metastasis of the tumor;\n4. No contraindications to general anesthesia;\n5. Patients with cosmetic demands.","75 Years",{"count":283,"type":19},170,[180],"The objective of this research is to investigate the clinical outcomes of modified surgical techniques such as omitting the cervical linea alba suture in transthoracic endoscopic thyroidectomy. Furthermore, the study requires the collection of normal thyroid tissues, benign and malignant thyroid tumors, and lymph nodes to further clarify the mechanisms associated with the initiation, progression, metastasis, and recurrence of thyroid cancer.",[23,287,288],"Lymph Node Metastasis","Carcinogenesis","2024-06-20",{"date":291,"type":29},"2024-06-21",{"date":293,"type":29},"2023-04-01",{"date":250,"type":19},{"name":223,"class":36},{"id":297,"slug":298,"hasResults":11,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":4,"eligibilityCriteria":302,"healthyVolunteers":11,"sex":15,"minAge":204,"maxAge":44,"enrollmentInfo":303,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":305,"conditions":306,"keywords":307,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":59},"100538115","prediction-of-lymph-node-metastasis-in-patients-with-thyroid-malignancy-by-a-new-scale-100538115","NCT06286631","Prediction of Lymph Node Metastasis in Patients With Thyroid Malignancy by a New Scale","Quantitative Rating Scale Based on Preoperative Prediction of Lymph Node Dissection in Patients With Thyroid Cancer","Inclusion Criteria:\n\n* Papillary thyroid cancer\n* Conscious and able to communicate normally\n* Age 16-80 years\n\nExclusion Criteria:\n\n* Preoperative or postoperative pathology suggests other types of tumors, such as medullary carcinoma or undifferentiated carcinoma.\n* Less than 16 years of age",{"count":304,"type":19},800,"The incidence of papillary thyroid cancer (PTC) has been on the rise in recent years, and 20%-50% of PTC patients will have lymph node metastasis. Lymph node involvement in PTC patients is usually related to the recurrence of PTC after surgery, and 30% of patients recur without lymph node dissection, with the risk of central cervical lymph node metastasis being the greatest, so it seems to be a good choice to perform lymph node dissection on patients after thyroidectomy, but in fact, there are controversies at home and abroad as to whether to perform lymph node dissection or not. The 2021 Chinese Society of Clinical Oncology (CSCO) guidelines for the diagnosis and treatment of differentiated thyroid cancer state that prophylactic central lymph node dissection (PCND) may increase the incidence of postoperative complications, but due to the high metastatic rate of PTC and the ability of PCND to effectively prevent recurrence and reoperation, countries in the East Asian region perform prophylactic lymph node dissection on almost all patients with PTC. However, for more countries in Europe and the United States, performing PCND has become a non-essential, individualized option. The aim of this study is to collect multifactorial data from more than 1,000 patients who have undergone previous thyroidectomy from 2021 to 2023, and to develop a novel scoring scale that can be used to individualize patients' scores based on a variety of factors prior to surgery, so that patients can be more accurately predicted to have lymph node metastasis and need prophylactic lymph node dissection prior to surgery, and patients who do not need dissection can avoid surgery. For patients who do not need lymph node dissection, complications caused by surgery can be avoided, while for patients who do have lymph node metastasis, recurrence of their cancer can be prevented. This will change the status quo of not being able to accurately determine the actual situation through simple preoperative examination or performing prophylactic lymph node dissection for all PTC patients.",[23],[23,308,309,310,311],"pre-operative","Prophylactic lymph node dissection","lymphatic node transfer","Multi-factor data","2024-02-22",{"date":314,"type":29},"2024-02-29",{"date":316,"type":29},"2023-05-01",{"date":318,"type":19},"2026-10-01",{"name":223,"class":36}]